Exchange: NASDAQ·Updated 07:47 PM EDT
ACIU logo

ACIUAC Immune SA

$2.36
$0.05
(2.08%)
Today
Closed $2.36
$0.00
(0.00%)
After Hours
EarningsAug 4
Mkt Cap$245.27M
Vol64,290.00
News
all
press releases
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
More News
News Placeholder
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.
Zacks
News Placeholder
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
Zacks
News Placeholder
INDV Stock: What Sublocade Growth Signals for 2026
Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.
Zacks
News Placeholder
AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
News Placeholder
Agilent Technologies Q2 Earnings Beat Estimates, Revenues Up Y/Y
A beats Q2 earnings and revenue estimates as recurring revenue hits 66% of sales, but shares lost despite raised fiscal 2026 guidance.
Zacks
News Placeholder
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
News Placeholder
AC Immune CEO Andrea Pfeifer To Retire, Board Chair Martin Z gel To Be Interim CEO
(RTTNews) - Tuesday, AC Immune SA (ACIU) announced that Chief Executive Officer Andrea Pfeifer has decided to retire from her role at the upcoming Annual General Meeting to spend more time with her...
Nasdaq News: Markets
News Placeholder
HC Wainwright Has Positive View of AC Immune FY2027 Earnings
AC Immune (NASDAQ:ACIU - Free Report) - Stock analysts at HC Wainwright raised their FY2027 earnings estimates for shares of AC Immune in a report issued on Monday, May 4th. HC Wainwright analyst A...
MarketBeat
News Placeholder
BTIG Research Reaffirms "Buy" Rating for AC Immune (NASDAQ:ACIU)
BTIG Research restated a "buy" rating and set a $8.00 price objective on shares of AC Immune in a research report on Monday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.